Georgios Mavraganis1 · Dimitrios Bampatsias1,2 · Christina Konstantaki1 · Kamil Stankowski3,4 ·Stavros Athanasopoulos1 · Chrysoula Moustou1 · Alexandros Alexandropoulos1 · Stefano Figliozzi3,4 ·Angelos Soranides1 · Ioannis Petropoulos1 · Dimitrios Klettas5 · Kimon Stamatelopoulos1,6 ·Georgios Georgiopoulos1,7
Received: 12 December 2025 / Accepted: 15 March 2026 © The Author(s) 2026
Abstract
Introduction Diabetic cardiomyopathy (DCM) often evades diagnosis before manifestation of clinical symptoms. In this study we explored how cardiometabolic traits influence early cardiac structure and function in asymptomatic people living with diabetes (PwD), using advanced imaging.
Methods We conducted a cross-sectional study of 88 participants: 57 people living with type 2 diabetes (PwT2D), 16 people living with type 1 diabetes (PwT1D) and 15 controls. All subjects underwent transthoracic echocardiography and/or cardiac magnetic resonance (CMR) imaging. Strain analysis, perfusion indices, and tissue characterization (T1, T2, and extracellular volume) were assessed. Arterial stiffness via pulse wave velocity (PWV), ventricular-arterial coupling (VAC), circulating biomarkers and liver fibrosis indices were evaluated.
Results PwD had lower cardiac index than controls. Global longitudinal strain (GLS) and global radial strain were lower in both diabetes mellitus (DM) groups, while left atrial strain was most impaired in PwT2D (β-coefficient= − 11.77, P=0.003). DM duration≥10 years was associated with worse GLS (β-coefficient= − 2.18, P=0.033) and right VAC (β-coefficient= − 0.27, P=0.027) after multivariable analysis. While tissue characterization and perfusion indices showed no significant group differences, tight glycemic control in PwD correlated with improved myocardial strain parameters. PwT2D exhib-ited greater arterial stiffness (β-coefficient=1.52, P=0.003). In PwD, elevated non-alcoholic fatty liver disease score cor-related with increased left ventricular mass (β-coefficient=6,195, P=0.022) and decreased left ventricular ejection fraction (LVEF) (β-coefficient= − 3.12, P=0.017). Higher growth differentiation factor levels were associated with reduced LVEF (β-coefficient= − 0.005, P=0.029).
Conclusion This multimodal imaging study highlights myocardial and vascular changes in asymptomatic PwD. Early com-prehensive cardiovascular assessment may help identify dysfunction before overt heart failure develops.
Keywords Diabetic cardiomyopathy · Cardiac magnetic resonance · Echocardiography · Arterial stiffness · Ventricular-arterial coupling · Liver fibrosis
Elena Succurro1,2 · Giuseppe Cersosimo3 · Paola Sarnelli4 · Francesco Brisinda1 · Ilaria Gattuso1 · Valeria Mazza1 ·Giuseppe Fabiano1 · Fiorella Iorio3 · Roberta Arena3 · Giovanni Mazzitello5 · Ramona Nicotera5 · Maria Capria1 ·Gianluigi Zaza6 · Michele Andreucci1 · Raffaele Mancini5 · Francesco Andreozzi1,2
Received: 22 December 2025 / Accepted: 16 March 2026© The Author(s) 2026
Aims To describe the main glycemic outcomes and the Quality of Life (QOL) observed in a cohort of people with type 1(T1D) or type 2 (T2D) insulin-treated diabetes under dialysis who started an Automated Insulin Delivery (AID) system.
Methods This is a longitudinal retrospective pilot real-world analysis of 14 individuals with T1D and T2D undergoingdialysis who began using an AID system to optimize glycemic control. All subjects used the MiniMed™ 780G system. Glu-cose metrics were collected at baseline, 3, 6, and 12 months after initiating the SmartGuard™ feature. The WHOQoL-Bref questionnaire was administered at the last follow-up to evaluate the QOL.
Results Out of the 14 people, 8 reached 1-year follow-up. Time in Range (TIR) increased from 63% at baseline to 69% at 12 months, Time Below Range <70 mg/dL (TBR70) decreased from 0.3% to 0%, and Time Above Range >250 mg/dL (TAR250) decreased from 6.7% to 3.9%. Seven out of eight subjects who reached a 12-month follow-up achieved all three glycemic targets for this fragile population (TIR>50%, TBR70<1% and TAR250<10%). At the last follow-up, 58.3% of the users were satisfied or very satisfied with their health status, versus only 25% with the previous treatment, and 81.7% had a good or very good QOL, whereas only 8.3% had a good QOL, and no one had a very good QOL with the previous
Conclusion This pilot real-world study showed how the use of an AID system is safe and can help to improve the glycemic outcomes and the QOL of people with diabetes in dialysis.
Keywords Automated insulin delivery system · End-stage kidney disease · Dialysis · Time in range · Diabetes mellitus · Quality of Life
Communicated by Salvatore Corrao, M.D
Elena Succurro
该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
1 Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Viale Europa, Catanzaro 88100, Italy
2 Research Center for the Prevention and Treatment of Metabolic Diseases (CR METDIS), University Magna Graecia of Catanzaro, Catanzaro, Italy
3 Azienda Ospedaliera Annunziata Cosenza, Cosenza, Italy
4 ASL Viterbo, Viterbo, Italy
5 ASP Catanzaro, Catanzaro, Italy
6 Department of Civil Engineering, University of Calabria, Rende, Italy
Authors
Ana Lívia de Oliveira
Larissa Loures Mendes
Michele Pereira Netto
Latricia Allen
Gail Powell-Cope
Miriam García Gonzalez
Isabel Casal Beloy
Alba Gómez Dovigo
Lorena Miguez Fortes
Arturo Gonzalez
Keywords
clinical study
伤口世界平台生态圈，以“关爱人间所有伤口患者”为愿景，连接、整合和拓展线上和线下的管理慢性伤口的资源，倡导远程、就近和居家管理慢性伤口，解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考，最终以医院当日公布为准。
网友、医生言论仅代表其个人观点，不代表本站同意其说法，请谨慎参阅，本站不承担由此引起的法律责任。
